VIENNA, Va., September 10, 2024--CEL-SCI to present new data for Multikine head & neck cancer immunotherapy at the European Society for Medical Oncology 2024 Congress.
HANSIZHUANG (serplulimab) is the world's first anti-PD-1 mAb for first-line treatment of ES- SCLC - HANSIZHUANG (serplulimab) is expected to become the first and only anti-PD-1 ...
Some results have been hidden because they may be inaccessible to you